# Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/hepatocellular-carcinoma-after-prior-sorafenib-treatment-incidence-healthcare/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Johannes Clouth,Astra M. Liepa,Guido Moeser,Heiko Friedel,Magdalena Bernzen,Jörg Trojan,Elena Garal‐Pantaler |
| Citations | 7 |
| DOI | 10.1186/s13561-018-0199-1 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://healtheconomicsreview.biomedcentral.com/track/pdf/10.1186/s13561-018-0199-1.pdf |
| OpenAlex ID | https://openalex.org/W2889291394 |
| PMID | 30151607 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Elena Garal‐Pantaler](https://scholariq.org/researchers/elena-garal-pantaler/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.